Stock Analiz

Palisade Bio, Inc. PALI

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$1.12Market cap $201M
Open the interactive analysis →

Palisade Bio, Inc. (PALI) is a healthcare company listed in the US with a market value of about $201M. In the twelve months to September 30, 2026 it had revenue of $500000 and net income of -$44M, a net margin of -8739.2%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).

Key numbers: a P/E of 1.2, 5-year revenue growth of -100% a year, a 5-year average ROIC of -158%.

About Palisade Bio

Palisade Bio is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $18833 in 2014 to $250000 in 2023, growth of about 33.3% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 94758% over three years (dilution for shareholders).

Score: 1.4 / 5

Value2/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)1.2
Forward P/E—
P/FCF—
P/S401.6
P/B1.8
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-13.2%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4920.0%
ROIC (5-yr avg.)-157.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$500000$0$0$250000$0—$13520$15394$260000$260000$16246
Net income-$44M-$17M-$14M-$12M-$14M-$27M-$10M-$8M-$5M-$16M-$21M
Free cash flow-$26M—-$12M-$11M-$13M-$15M-$5M—-$8M-$13M-$16M
EPS (diluted)$0.91$-0.30$-10.19$-27.01$-247.95$-2546.10$-2790.01$-2850.01$-5655.03$-20883.14$-44028.61
Net margin-8739.2%——-4920.0%——-76346.1%-54252.6%-1894.1%-6025.4%-129700.0%
ROIC—-11.0%-154.8%-89.6%-97.1%-437.1%——-107.9%-123.5%-108.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $8.70, 677% above the current price; targets range from $5.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Palisade Bio’s P/E ratio?

About 1.2, based on the last twelve months of diluted earnings per share.

Does Palisade Bio pay a dividend?

Not currently.

Is Palisade Bio a good stock to buy?

We do not give buy or sell advice. Palisade Bio scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.